Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

Inclusion Criteria: * Non-smokers with clinical diagnosis of Type 2 diabetes mellitus for \>or= to 6 months * Stable regimen of metformin for \> or = to 1000mg/day or maximum tolerated dose) and a secretagogue \< or = 1/2 the maximum manufacturer-recommended daily dose without any dose adjustments within the preceding 6 wks. * Fixed dose combination products of metformin and sulfonylurea are acceptable as long as each individual dose meets inclusion criteria * HbA1c \>or= to 7.5% and \< or= to 11.0% * BMI \< or = to 40kg/m2. * FEV1\> or = to 70%, Total Lung capacity and \> or =80% DLco \> or= to 70% Exclusion Criteria: * Treatment with any type of anti-diabetic therapy, other than metformin \& secretagogues within the preceding 12 weeks * Serum creatinine \> 1.4mg/dL in female subjects and \>1.5mg/dL in male subjects * History of chronic obstructive pulmonary disease, clinically proven asthma and/or any other clinically important pulmonary function testing and/or radiologic findings * Evidence of serious complications of diabetes (e.g. autonomic neuropathy)